Quilizumab (Asthma) - Forecast and Market Analysis to 2023
|出版日期||內容資訊||英文 67 Pages
|Quilizumab(氣喘治療藥):市場預測與分析 Quilizumab (Asthma) - Forecast and Market Analysis to 2023|
|出版日期: 2014年08月31日||內容資訊: 英文 67 Pages||
GlobalData has released its new PharmaPoint Drug Evaluation report, "Quilizumab (Asthma) - Forecast and Market Analysis to 2023". The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.
Roche's quilizumab is an anti-M1 prime humanized mAb designed to eliminate B cells that would otherwise develop into plasma cells and produce IgE. This is a different mechanism from binding to and neutralizing existing IgE, as does Novartis' Xolair. IgE is important in the development of allergic asthma, as it binds to mast cells and basophils, which play a significant role in the pathogenesis of asthma. IgE ultimately triggers the release of histamines, prostaglandins, and leukotrienes, which produce airway inflammation and obstruction. Anti-IgE therapy is designed to block IgE at the beginning of its cascade. Roche is already an established player in the biological segment of the asthma market, and this is its second biological pipeline product entering late-phase development.